Endometrial Cancer Diagnostics Market: By Condition (Endometrioid Carcinoma, Serous Adenocarcinoma, Adenosquamous Carcinoma, Carcinomasarcoma), By Test (Hysteroscopy, Endometrial Biopsy, Dilation and Curettage, Ultrasound, CT Scan, MRI), By End-user (Diagnostic Centers, Hospitals, Ambulatory Surgical Centers) and Geography   

Purchase Option

$ 4400
$ 6600
$ 8900

Endometrial Cancer Diagnostics Market size was valued at USD 21.4 billion in 2022 and estimated to reach at USD 28.4 billion by 2029, growing at a significant CAGR of 5.4% From 2023-2029. Endometrial Cancer is the most common form of uterine cancer as the endometrium is part of the uterus. Endometrial cancer is often called uterine cancer. It is the most commonly diagnosed gynecologic cancer. Endometrial cancer forms when cells in the inner lining of the uterus (endometrium) begin to grow out of control. Unlike breast and prostate cancer where screening tests are available to the general population endometrial cancer is most commonly diagnosed at endometrial biopsy in symptomatic patients. No generally applicable screening test is available. Among all test types hysteroscopy is most commonly recommended uterine cancer diagnostic test.

According to the American Cancer Society, in 2017, about 61380 new cases of uterine cancer were diagnosed and around 10,000 were dead. According to WHO, developed regions such as North America and Europe registers greater incidence rate for endometrial cancer due to lifestyle changes adopted by women. Women with abnormal vaginal bleeding are detected with endometrial cancer at an early stage. Endometrial cancer is the sixth most common cancer in women worldwide, according to statistics. Because of the increased prevalence of Endometrial Cancer Diagnostics Market is predicted to grow significantly. Other key factors contributing to the market's growth include rising female obesity, increased menopausal hormone therapy, changes in sedentary lifestyle, socioeconomic factors, rising consumption of unhealthy diet, rising occurrence of Polycystic Ovarian Syndrome (PCOS), and rising prevalence of breast or ovarian tumour. Another condition that contributes to the development of endometrial cancer is diabetes. Endometrial cancer is four times more likely in diabetes women than in non-diabetic women, according to the American Cancer Society. Endometrial cancer is caused by such factors in women.

Endometrial Cancer Diagnostics Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

5.4%

Largest Market

North-America

Fastest Growing Market

Asia Pacific
Endometrial Cancer Diagnostics Market Dynamics

Increase in the prevalence and incidence of endometrial cancer propels the growth of the endometrial cancer diagnostics market globally. As per the stats of American Cancer Society, in 2012, about 47,130 new cases of endometrial cases were diagnosed and 8010 women died because of it. Furthermore increase in awareness regarding uterine diseases, availability of various treatment options and early diagnostic options drives the growth of the globally. Moreover increase in healthcare expenditure, technological advancements and developments and advanced healthcare services also propels the market growth of endometrial cancer diagnostics globally. However, low accuracy rate in the results of diagnostic tests, high cost associated with the tests and treatments, adverse effects and lack of awareness about innovative technologies may hinder the growth of the globally.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Endometrial Cancer Diagnostics Market Segmentation

By Condition
  • Endometrioid Carcinoma
  • Serous Adenocarcinoma
  • Adenosquamous Carcinoma
  • Carcinomasarcoma
By Test
  • Hysteroscopy
  • Endometrial Biopsy
  • Dilation and Curettage
  • Ultrasound
  • CT Scan
  • MRI
By End user
  • Diagnostic Centers
  • Hospitals
  • Ambulatory Surgical Centers

Frequently Asked Questions

The endometrial cancer diagnostics market is projected to expand at a CAGR of 5.4% during the forecast period  

Abbott Laboratories, Ariad Pharmaceuticals, Merck, Becton, Dickinson, Siemens Healthcare

Asia Pacific is the fastest-growing region for endometrial cancer diagnostics market

1.Executive Summary
2.Global Endometrial Cancer Diagnostics Market Introduction 
2.1.Global Endometrial Cancer Diagnostics Market  - Taxonomy
2.2.Global Endometrial Cancer Diagnostics Market  - Definitions
2.2.1.Type
2.2.2.Test
2.2.3.End-user
2.2.4.Region
3.Global Endometrial Cancer Diagnostics Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Endometrial Cancer Diagnostics Market Analysis, 2018-2022 and Forecast 2023-2029
4.1.  Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Endometrial Cancer Diagnostics Market  By Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Endometrioid Carcinoma
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Serous Adenocarcinoma
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Adenosquamous Carcinoma
5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Carcinomasarcoma
5.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
6.Global Endometrial Cancer Diagnostics Market  By Test, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Hysteroscopy
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Endometrial Biopsy
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Dilation and Curettage
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Ultrasound
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. CT Scan
6.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
6.6.  MRI
6.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.6.3. Market Opportunity Analysis 
7.Global Endometrial Cancer Diagnostics Market  By End-user, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. Diagnostic Centers
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Hospitals
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Ambulatory Surgical Centers
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8.Global Endometrial Cancer Diagnostics Market  By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Endometrial Cancer Diagnostics Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Endometrioid Carcinoma
9.1.2.Serous Adenocarcinoma
9.1.3.Adenosquamous Carcinoma
9.1.4.Carcinomasarcoma
9.2.  Test Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Hysteroscopy
9.2.2.Endometrial Biopsy
9.2.3.Dilation and Curettage
9.2.4.Ultrasound
9.2.5.CT Scan
9.2.6. MRI
9.3.  End-user Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Diagnostic Centers
9.3.2.Hospitals
9.3.3.Ambulatory Surgical Centers
9.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Endometrial Cancer Diagnostics Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Endometrioid Carcinoma
10.1.2.Serous Adenocarcinoma
10.1.3.Adenosquamous Carcinoma
10.1.4.Carcinomasarcoma
10.2.  Test Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Hysteroscopy
10.2.2.Endometrial Biopsy
10.2.3.Dilation and Curettage
10.2.4.Ultrasound
10.2.5.CT Scan
10.2.6. MRI
10.3.  End-user Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Diagnostic Centers
10.3.2.Hospitals
10.3.3.Ambulatory Surgical Centers
10.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
11.Asia Pacific (APAC) Endometrial Cancer Diagnostics Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Endometrioid Carcinoma
11.1.2.Serous Adenocarcinoma
11.1.3.Adenosquamous Carcinoma
11.1.4.Carcinomasarcoma
11.2.  Test Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Hysteroscopy
11.2.2.Endometrial Biopsy
11.2.3.Dilation and Curettage
11.2.4.Ultrasound
11.2.5.CT Scan
11.2.6. MRI
11.3.  End-user Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Diagnostic Centers
11.3.2.Hospitals
11.3.3.Ambulatory Surgical Centers
11.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Endometrial Cancer Diagnostics Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Endometrioid Carcinoma
12.1.2.Serous Adenocarcinoma
12.1.3.Adenosquamous Carcinoma
12.1.4.Carcinomasarcoma
12.2.  Test Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Hysteroscopy
12.2.2.Endometrial Biopsy
12.2.3.Dilation and Curettage
12.2.4.Ultrasound
12.2.5.CT Scan
12.2.6. MRI
12.3.  End-user Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Diagnostic Centers
12.3.2.Hospitals
12.3.3.Ambulatory Surgical Centers
12.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Endometrial Cancer Diagnostics Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
13.1. Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Endometrioid Carcinoma
13.1.2.Serous Adenocarcinoma
13.1.3.Adenosquamous Carcinoma
13.1.4.Carcinomasarcoma
13.2.  Test Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Hysteroscopy
13.2.2.Endometrial Biopsy
13.2.3.Dilation and Curettage
13.2.4.Ultrasound
13.2.5.CT Scan
13.2.6. MRI
13.3.  End-user Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Diagnostic Centers
13.3.2.Hospitals
13.3.3.Ambulatory Surgical Centers
13.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Abbott Laboratories (U.S)
14.2.2.Ariad Pharmaceuticals, Inc. (U.S)
14.2.3.Merck & Co., Inc. (U.S)
14.2.4.Becton, Dickinson & Co. (U.S)
14.2.5.Siemens Healthcare Inc. (Germany)
14.2.6.Hoffman-La Roche Ltd. (Switzerland)
14.2.7.GlaxoSmithKline Plc., etc. (UK)
15. Research Methodology 
16. Appendix and Abbreviations 
  • Abbott Laboratories (U.S)
  • Ariad Pharmaceuticals, Inc. (U.S)
  • Merck & Co., Inc. (U.S)
  • Becton, Dickinson & Co. (U.S)
  • Siemens Healthcare Inc. (Germany)
  • Hoffman-La Roche Ltd. (Switzerland)
  • GlaxoSmithKline Plc., etc. (UK)

Adjacent Markets